3 min read
Vietnam continues to attract pharmaceutical companies seeking growth opportunities in Southeast Asia. However, obtaining approval from the Drug Administration of Vietnam (DAV) can become challenging when submission dossiers contain overlooked deficiencies.
The Drug Administration of Vietnam (DAV) has updated its Regulatory framework under Circular 08/2022/TT-BYT and subsequent decrees. While these aim to streamline applications, they have caused unexpected bottleneck delays for foreign pharmaceutical companies.
The DAV has limited applicants to a maximum of two rounds of supplementation queries before rejection, and firms have a shortened 6-month hard deadline to respond to deficiency letters. Missing subtle dossier details can easily kill a registration or add years to the timeline for approval.
Understanding these hidden dossier issues early can help companies improve submission readiness and reduce avoidable delays.
What Are Hidden Dossier Issues?
Hidden dossier issues are gaps, inconsistencies, or documentation deficiencies that may not be obvious during dossier preparation but can trigger DAV queries, requests for clarification, or multiple rounds of supplementation during review.
Even well-developed products can face setbacks if submission packages do not fully align with Vietnam's Regulatory expectations.
- Legalization, Apostille, and Address Mismatches
The DAV is imperatively strict about administrative consistency. If the manufacturing site address on your Certificate of Pharmaceutical Product (CPP) or Good Manufacturing Practice (GMP) certificate uses different abbreviations or formatting from the ASEAN Common Technical Dossier (ACTD) forms, the dossier is flagged. Rejections frequently happen due to invalid, expired, or improperly processed paperwork that does not follow specific Vietnamese Embassy formats.
- Direct Translation of Foreign Product Information (PI)
Many companies directly translate their US FDA PI or EU SmPC into Vietnamese. However, DAV requires local product labels and package inserts to be according to local rules (Circular 01/2018/TT-BYT). Direct translations often use therapeutic terminology, storage conditions, or indications that do not exactly match pre-approved Vietnamese medical terminologies, leading to unexpected automatic technical review failures.
- Stability Data Incompatibilities (Climatic Zone IVb)
Vietnam belongs to the WHO Climatic Zone IVb (Hot and Very Humid: 30°C / 75% RH). Global manufacturers often submit long-term stability data tailored only for Zone II or Zone IVa. If the submission lacks real-time or zone-appropriate data for the proposed shelf-life under Zone IVb conditions, the DAV will halt the process, requiring local repackaging and modifications or fresh zone-specific testing.
- Missing Reference-Country Bridging Data
Foreign submissions utilize the standard evaluation pathway that links back to approval timelines in reference markets. Under newer regulations, dossiers must be filed in Vietnam within 5 years of first approval by a Stringent Regulatory Authority (SRA) or the EMA. Furthermore, the dossier should include full assessment reports from the SRA and a comprehensive comparison table showing exact similarities between the versions.
- Active Pharmaceutical Ingredient (API) Open-Part DMF Gaps
Under the ACTD format (Parts I to IV), technical data surrounding raw drug materials must be accurate and consistent. Delays from the open part of the Drug Master File (DMF) if the supplier’s analytical validation data, impurity profiles, or residual solvent data do not align with Vietnam's specific pharmacopeia standards (or recognized reference standards), the entire dossier evaluation stops while waiting on third-party suppliers to clarify technical parameters.
What Are the Common Dossier Issues?
1. Incomplete Documentation
Missing supporting documents, outdated certificates, or improperly executed authorization documents can result in review interruptions.
2. Inconsistencies Across Submission Modules
Differences in product information, specifications, manufacturing details, or labeling documents can lead to additional questions from reviewers.
3. Limited Review of Local Requirements
Using global dossiers without assessing Vietnam-specific requirements may increase the likelihood of deficiency notices.
4. Translation and Localization Errors
Inaccurate translations, inconsistent terminology, or formatting discrepancies can affect the clarity and acceptability of submitted documents.
5. Insufficient Dossier Quality Checks
Without a thorough pre-submission review, minor errors can evolve into significant approval hurdles.
Why Does This Matter?
Delays in DAV approvals can affect launch timelines, supply planning, and overall market entry strategies.
According to observations highlighted in guidance related to dossier evaluations, many submissions require supplementation after initial review due to quality concerns and incomplete documentation. Improving dossier quality before filing can help minimize these challenges.
How Can Companies Prevent These Issues?
Organizations can strengthen submission readiness by:
- Conducting comprehensive dossier gap assessments
- Reviewing submissions against Vietnam-specific requirements
- Implementing robust quality control processes
- Ensuring accurate translation and localization
- Performing detailed dossier due diligence before filing
Final Thoughts
Successful registration in Vietnam requires more than compiling documents—it requires a strategic approach to dossier preparation.
By identifying hidden dossier issues early and strengthening submission quality, companies can reduce avoidable delays and navigate the DAV review process more efficiently.
Planning a Vietnam DAV Submission?
Freyr Solutions supports pharmaceutical companies with Vietnam Regulatory strategy, dossier gap assessments, submission readiness reviews, translation and localization support, and end-to-end registration assistance.
Connect with Freyr's experts to identify hidden dossier risks early and help keep your Vietnam market entry plans on track.